Zobrazeno 1 - 10
of 54
pro vyhledávání: ''
Autor:
Satoshi Teramukai, Hideki Ueno, Seiichi Shinji, Kenichi Sugihara, Kenta Murotani, Hiroyuki Uetake, Megumi Ishiguro, Tomohisa Egawa, Yoshihiko Nakamoto, Osamu Ikawa, Shigeyuki Matsui, Keigo Yasumasa, Toshiaki Ishikawa, Masanori Kotake, Kohei Murata, Chu Matsuda, Naohiro Tomita, Kiyotaka Kurachi, Eiji Nakatani
Publikováno v:
Journal of Clinical Oncology
PURPOSE The International Union Against Cancer highlighted tumor budding as a tumor-related prognostic factor. International assessment criteria for tumor budding were recently defined by the 2016 International Tumor Budding Consensus Conference (ITB
Autor:
Edwin J. Squirewell, Louis A. Schenck, Clark C. Otley, Joel B. Heim, Mark R. Pittelkow, Jørgen Lock-Andersen, Amy L. Weaver, Mark A. Cappel, Alexander Meves, Vera J. Suman, Ekaterina Nikolova, Ditte Marie Saunte, Nille Behrendt
Publikováno v:
Journal of Clinical Oncology. 33:2509-2515
Purpose Less than 20% of patients with melanoma who undergo sentinel lymph node (SLN) biopsy based on American Society of Clinical Oncology/Society of Surgical Oncology recommendations are SLN positive. We present a multi-institutional study to disco
Integrative and Comparative Genomic Analysis of Lung Squamous Cell Carcinomas in East Asian Patients
Autor:
Young-Wook Kim, Andrey Sivachenko, Hong Kwan Kim, Gad Getz, Yeong Kyung Yoo, Jhingook Kim, Yoon-La Choi, Kyu Sik Kim, Yong Soo Choi, Jong Mu Sun, Michael S. Lawrence, Scott L. Carter, Keunchil Park, Chip Stewart, Matthew D. Wilkerson, Young Mog Shim, Petar Stojanov, Matthew Meyerson, Yoomi Lee, Kwhanmien Kim, Jin Seok Ahn, Sukki Cho, Jaegil Kim, D. Neil Hayes, Young-Chul Kim, Aaron McKenna, Sang Yun Song, Ji Ae Yoon, Myung-Ju Ahn, Kook Joo Na, Chandra Sekhar Pedamallu, Peter S. Hammerman, In-Jae Oh, Kristian Cibulskis
Publikováno v:
Journal of Clinical Oncology. 32:121-128
Purpose Lung squamous cell carcinoma (SCC) is the second most prevalent type of lung cancer. Currently, no targeted therapeutics are approved for treatment of this cancer, largely because of a lack of systematic understanding of the molecular pathoge
Autor:
C. Millward, Greg Yothers, Kim M. Clark-Langone, Steven Shak, Margarita Lopatin, Saima Sharif, Michael O’Connell, Norman Wolmark, Mark Lee, Soonmyung Paik
Publikováno v:
Journal of Clinical Oncology. 31:4512-4519
Purpose Accurate assessments of recurrence risk and absolute treatment benefit are needed to inform colon cancer adjuvant therapy. The 12-gene Recurrence Score assay has been validated in patients with stage II colon cancer from the Cancer and Leukem
Publikováno v:
Journal of Clinical Oncology. 31:2554-2562
Purpose Molecular screening techniques are available to identify hereditary Lynch syndrome in people with newly diagnosed colorectal cancer (CRC). We aimed to determine whether decisions of patients or clinicians reduced detection of Lynch syndrome.
Autor:
Matthew R. Cooperberg, Steven Stone, Julia Reid, Azita Djalilvand, Alexander Gutin, Jerry S. Lanchbury, Jeffry P. Simko, Gregory P. Swanson, Satish Bhatnagar, Peter R. Carroll, Janet E. Cowan
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 31, iss 11
Cooperberg, MR; Simko, JP; Cowan, JE; Reid, JE; Djalilvand, A; Bhatnagar, S; et al.(2013). Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. Journal of Clinical Oncology, 31(11), 1428-1434. doi: 10.1200/JCO.2012.46.4396. UCSF: Retrieved from: http://www.escholarship.org/uc/item/4vs034qj
Cooperberg, MR; Simko, JP; Cowan, JE; Reid, JE; Djalilvand, A; Bhatnagar, S; et al.(2013). Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. Journal of Clinical Oncology, 31(11), 1428-1434. doi: 10.1200/JCO.2012.46.4396. UCSF: Retrieved from: http://www.escholarship.org/uc/item/4vs034qj
Purpose We aimed to validate a previously described genetic risk score, denoted the cell-cycle progression (CCP) score, in predicting contemporary radical prostatectomy (RP) outcomes. Methods RNA was quantified from paraffin-embedded RP specimens. Th
Autor:
Ute Sartorius, Michael Schlichting, Sabine Tejpar, Ilhan Celik, Eric Van Cutsem, Carsten Bokemeyer
Publikováno v:
Journal of Clinical Oncology. 30:3570-3577
Purpose We investigated in the first-line setting our previous finding that patients with chemorefractory KRAS G13D–mutated metastatic colorectal cancer (mCRC) benefit from cetuximab treatment. Methods Associations between tumor KRAS mutation statu
Autor:
Michael D. Radmacher, Sebastian Schwind, Kati Maharry, Susan P. Whitman, Klaus H. Metzeler, Joseph O. Moore, Richard A. Larson, Deedra Nicolet, Meir Wetzler, Andrew J. Carroll, Heiko Becker, Krzysztof Mrózek, Jihane Khalife, Michael A. Caligiuri, Jessica Kohlschmidt, Maria R. Baer, Jonathan E. Kolitz, Bayard L. Powell, Guido Marcucci, Jason H. Mendler, Thomas H. Carter, Clara D. Bloomfield
Publikováno v:
Journal of Clinical Oncology. 30:3109-3118
Purpose To determine the association of RUNX1 mutations with therapeutic outcome in younger and older patients with primary cytogenetically normal acute myeloid leukemia (CN-AML) and with gene/microRNA expression signatures. Patients and Methods Youn
Autor:
Arnaud Roth, Mauro Delorenzi, Eva Budinská, Tao Xie, Scott L. Weinrich, Sabine Tejpar, Fred T. Bosman, Eric Van Cutsem, Heather Estrella, Vlad Popovici, Graeme Hodgson
Publikováno v:
Journal of Clinical Oncology. 30:1288-1295
Purpose Our purpose was development and assessment of a BRAF-mutant gene expression signature for colon cancer (CC) and the study of its prognostic implications. Materials and Methods A set of 668 stage II and III CC samples from the PETACC-3 (Pan-Eu
Autor:
Dennis A. Carney, Evelyn McKeegan, William G. Wierda, Todd A. Busman, Sari H. Enschede, Jennifer R. Brown, David C.S. Huang, Yue Cui, John F. Seymour, Rod A. Humerickhouse, Simon He, Andrew W. Roberts, Andrew Krivoshik, Thomas J. Kipps, Seong Lin Khaw, Hao Xiong
Publikováno v:
Journal of Clinical Oncology. 30:488-496
Purpose BCL2 overexpression is a hallmark of chronic lymphocytic leukemia (CLL). The novel BH3 mimetic navitoclax (ABT-263) specifically inhibits BCL2 and related proteins BCL-xl and BCL-w, potently inducing apoptosis of CLL cells in vitro. A phase I